Table 4.
The effect of comorbidity on standard CVD screening
| Number of patients (n (%)) | Unadjusted (OR (95% CI)) | Age and gender adjusted (OR (95% CI)) | |
|---|---|---|---|
| No RA or DM |
1071 (67.0) |
1.00 |
1.00 |
| RA only |
353 (22.1) |
0.96 (0.74, 1.26) |
0.96 (0.72, 1.24) |
| DM only |
127 (7.9) |
12.15 (7.53, 19.61) |
11.14 (6.86, 18.11) |
| RA +DM |
48 (3.0) |
14.91 (6.62, 33.61) |
15.32 (6.70, 35.02) |
| No RA or HTN |
651 (40.7) |
1.00 |
1.00 |
| RA only |
192 (12.0) |
1.11 (0.74, 1.68) |
1.16 (0.77, 1.76) |
| HTN only |
547 (34.2) |
5.34 (4.11, 6.94) |
4.82 (3.67, 6.35) |
| RA +HTN |
209 (13.1) |
4.36 (3.11, 6.11) |
3.82 (2.70, 5.42) |
| No RA or HLP |
800 (50.0) |
1.00 |
1.00 |
| RA only |
267 (16.7) |
1.09 (0.76, 1.58) |
1.07 (0.68, 1.66) |
| HLP only |
398 (24.9) |
12.31 (9.25, 16.38) |
9.78 (6.98, 12.87) |
| RA +HLP | 134 (8.4) | 11.50 (7.62, 17.35) | 8.15 (5.40, 12.31) |
RA – Rheumatoid arthritis; HTN – hypertension; HLP – hyperlipidaemia; OR – odds ratio; CI – confidence interval.